2:45 NULISA Neurology Biomarker Platform – Brain-derived pTau217 and High-plex Neurodegenerative Disease and Neuroinflammatory Biomarker Analysis
Time: 2:45 pm
day: Conference Day 1
Details:
- NULISA™: Ultra-sensitive femtogram level detection with barcode-based high-plex biomarker analysis
- First brain-derived (BD) pTau217 assay for highest accuracy blood-based Alzheimer's detection
- CNS Disease Panel: Unique in its coverage of hundreds of proteins involved in neurodegeneration, inflammation, vascular and synaptic dysfunction. New BD-Tau181,217, 231, total assays
- Inflammation Panel: Comprehensive coverage of cytokines and key immune markers underlying neuroinflammatory disease
- NULISA platform: Unmatched ability to translate targeted neuroimmune proteomic discoveries into low-plex quantitative assays on the same ARGO HT System
- ARGO HT System: Fully automated instrument for running single-, low-, and high-plex assays
- NULISA IVD and ARGO DX in development with funding from Gates Ventures and DxA
